Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.53 |
| ▸ | CPA1 | P15085 | 1/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.53 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 3/20 | 0.48 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | CASP9 | P55211 | 1/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.46 |
| ▸ | NPY1R | P25929 | 1/20 | 0.45 |
| ▸ | NPY2R | P49146 | 1/20 | 0.45 |
| ▸ | NPY4R | P50391 | 1/20 | 0.45 |
| ▸ | IL1RN | P18510 | 1/20 | 0.45 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30622615 | 0.88 | BACE1 (0.58) | ACEBACE1BACE2F2CASP1 | |
| SCHEMBL30565308 | 0.87 | ACE (0.57) | ACEMMECPA1ACE2ANPEP | |
| SCHEMBL29655823 | 0.86 | ENPEP (0.52) | ACEMMECPA1ACE2NAALAD2 | |
| SCHEMBL29370021 | 0.86 | NAALAD2 (0.62) | ACEMMECPA1ACE2NAALAD2 | |
| SCHEMBL31613781 | 0.86 | NAALAD2 (0.62) | ACEMMECPA1ACE2NAALAD2 | |
| SCHEMBL29822555 | 0.86 | ACE (0.70) | ACEMMECPA1ACE2 | |
| SCHEMBL30832636 | 0.85 | ACE (0.53) | ACEMMECPA1ACE2CASP1 | |
| SCHEMBL10617903 | 0.85 | ACE (0.59) | ACEMMECPA1ACE2 | |
| SCHEMBL10617891 | 0.85 | ACE (0.59) | ACEMMECPA1ACE2 | |
| SCHEMBL7678279 | 0.85 | ACE (0.65) | ACEMMECPA1ACE2ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220073446-A1 | Antigen Delivery Vectors and Constructs | ALTIMMUNE UK LIMITED (GB) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073446-A1 | Antigen Delivery Vectors and Constructs | LY96, CD74, CD69 | ACE 1068/4885MME 473/4885CPA1 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.